Siplizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Siplizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from rat)
TargetCD2
Clinical data
ATC code
  • none
Identifiers
CAS Number
  • 288392-69-8 ☒N
ChemSpider
  • none
UNII
KEGG
 ☒NcheckY (what is this?)  (verify)

Siplizumab (MEDI-507) is a novel monoclonal antibody with a human IgG1, kappa directed to CD2. The agent has shown potent immunomodulatory effects, selectively suppressing the function of T and NK cells, and is currently being tested as a possible treatment for psoriasis and in the prevention of graft-versus-host disease.[1]

References[edit]